C-THERAPY NIGHT CREAM
Gradually diminishes dark spots with 4% hydroquinone, and provides Vitamins C and Vitamin E to your skin while you sleep.
Prescription required. Contact your healthcare provider to purchase, or find a nearby physician who offers this product.
With Obagi-C Rx, you're on your way to healthier, refreshed, revitalized skin from cell to surface. Obagi-C Rx Systems promote skin rejuvenation from the inside out using a formulation of prescription-strength hydroquinone USP, 4%, which reduces the appearance of hyperpigmentation and age spots, combined with 10% L-Ascorbic Acid (Vitamin C)—the only topical antioxidant proven to stimulate collagen synthesis and protect your skin by minimizing future skin cell damage.
Strong inhibitor of melanin production that has long been established as the most effective ingredient for reducing and potentially eliminating melasma.
water (aqua), glycerin, cetyl alcohol, PPG-2 myristyl ether propianate, sodium lauryl sulfate, TEA-salicylate, latic acid, phenyl trimethicone, tocopheryl acetate, sodium metabisulfite, ascorbic acid, methylparben, disodium EDTA, propylparaben, saponins, BHT
IMPORTANT SAFETY INFORMATION
Obagi-C Rx C-Clarifying Serum (Normal to Oily & Normal to Dry) and C-Therapy Night Cream contains 4% hydroquinone
CONTRAINDICATIONS: People with prior history of sensitivity or allergic reaction to this product or any of its ingredients should not use it. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.
Please click here for full Prescribing Information for C-Clarifying Serum and C-Therapy Night Cream
- Avoid contact with eyes, nose, mouth, or lips. In case of accidental contact, patient should rinse eyes, nose, mouth, or lips with water and contact physician.
- Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.
- Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
PRECAUTIONS (ALSO SEE WARNINGS): Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation, which does not preclude treatment.
Pregnancy Category C: Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.
Nursing Mothers: It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.
Pediatric Usage: Safety and effectiveness in children below the age of 12 years have not been established.
Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.